Neural stimulator systems with an external magnetic coil to produce changing magnetic fields is applied outside the body, in conjunction with one or more tiny injectable objects that concentrates the induced electric or magnetic field to a highly-targeted location. These systems include a driver circuit for the magnetic coil that allows for high voltage and fast pulses in the coil, while requiring low-voltage power supply that may be powered by a wearable or portable external device, along with the coil and driver circuit.

Implantable medical devices (IMDs), systems, and methods for use therewith are disclosed. One such method is for use by a leadless pacemaker (LP) configured to perform conductive communication with another implantable medical device (IMD). The method includes the LP storing information that specifies when, within a cardiac cycle, the LP and the other IMD implanted in a patient are likely oriented relative to one another such that conductive communication therebetween should be successful. The method also includes the LP sensing a signal indicative of cardiac activity of the patient over a plurality of cardiac cycles, and outputting one or more conductive communication pulses, during a portion of at least one of the cardiac cycles, wherein the portion of the at least one of the cardiac cycles is identified based on the signal that is sensed and the information that is stored.

An implantable medical device comprises a communication module that comprises at least one of a receiver module and a transmitter module. The receiver module is configured to both receive from an antenna and demodulate an RF telemetry signal, and receive from a plurality of electrodes and demodulate a tissue conduction communication (TCC) signal. The transmitter module is configured to modulate and transmit both an RF telemetry signal via the antenna and a TCC signal via the plurality of electrodes. The RF telemetry signal and the TCC signal are both within a predetermined band for RF telemetry communication. In some examples, the IMD comprises a switching module configured to selectively couple one of the plurality of electrodes and the antenna to the receiver module or transmitter module.

The present invention provides an advancement in the art of cardiac pacemakers. The invention provides a novel and unobvious pacemaker system that comprises at least one pacemaker and that is, to a large extent, self-controlled, allows for long-term implantation in a patient, and minimizes current inconveniences and problems associated with battery life. The invention further includes a mechanism in which at least two pacemakers are implanted in a patient, and in which the pacemakers communicate with each other at the time of a given pacing or respiratory event, without any required external input, and adjust pacing parameters to respond to the patient's need for blood flow. The invention further provides a novel design for a pacemaker in which the pacemaker electrode is connected to the pacemaker body by a lead that is configured to allow the pacemaker to lie parallel to the epicardial surface and to reduce stress on the pacemaker and heart tissue.

An implantable medical device comprising a signal generator configured to generate and deliver anti-tachyarrhythmia pacing (ATP) to a heart of a patient and processing circuitry. The processing circuitry is configured to detect an enable event, responsive to detecting the enable event, enable the delivery of ATP by the signal generator, detect a disable event indicating that another implantable medical device cannot be relied upon to deliver an anti-tachyarrhythmia shock, and responsive to detecting the disable event, disable delivery of ATP.

Techniques are disclosed for determining, by an extracardiovascular implantable cardioverter defibrillator (ICD) implanted in a patient, whether one or more test therapy signals generated by another medical device implanted in the patient is detected. In response to detecting the one or more test therapy signals, the extracardiovascular ICD provides an indication that the extracardiovascular ICD has detected the one or more test therapy signals. In some examples, the indication is an audible tone provided to a clinician. In some examples, the other medical device is an intracardiac cardiac pacing device, and the one or more test therapy signals comprises a plurality of anti-tachycardia pacing (ATP) pulses.

In some examples, an implantable medical device determines that another medical device delivered an anti-tachyarrhythmia shock, and delivers post-shock pacing in response to the determination. The implantable medical device may be configured to both detect the delivery of the shock in a sensed electrical signal and, if delivery of the shock is not detected, determine that the shock was delivered based on detection of asystole of the heart. The asystole may be detected based on the sensed electrical signal. In some examples, an implantable medical device is configured to revert from a post-shock pacing mode to a baseline pacing mode by iteratively testing a plurality of decreasing values of pacing pulse magnitude until loss of capture is detected. The implantable medical device may update a baseline value of the pacing pulse magnitude for the baseline mode based on the detection of loss of capture.

A subcutaneous implant, including: (a) a circuitry unit having a first end, a second end, a conducting lateral side, and an opposing lateral side; (b) a first electrode, disposed on an outer surface of the circuitry unit and laterally circumscribing the circuitry unit at the first end; (c) a second electrode, disposed on the outer surface of the circuitry unit and laterally circumscribing the circuitry unit at the second end; (d) circuitry, disposed within the circuitry unit, and configured to be wirelessly powered to drive an electrical current between the electrodes; and (e) an insulating member, disposed on the opposing lateral side such that, on the opposing lateral side, each electrode is sandwiched between the insulating member and the circuitry unit, and the insulating member inhibits electrical conduction from the electrodes into the tissue. Other embodiments are also described.

A leadless neurostimulation (NS) device and method to manufacture the device is described. The leadless NS device has a first sub-unit (FU) and a second sub-unit (SU) separately and individually hermetically sealed. The FU and SU also include a flexible inter-connect that physically interconnects the FU and SU to one another. The leadless NS device also includes electrodes provided along the exterior surface of at least one of the first and second sub-units. The electrodes are configured to interface with nervous tissue in an epidural space of a patient and deliver stimulation pulses along the nervous tissue. At least partially housed within the FU includes a first subset of a power source, an energy management components, an electronics sub-system and telemetry component. Further, a second subset of the power source, energy management components, electronics sub-system and telemetry component are at least partially housed within the SU.

Described herein are implantable device networks that include two or implantable devices configured to modulate neural activity in a subject. The network includes at least one implantable device that can detect a detection signal, such as an electrophysiological signal or a physiological condition. The network also includes a second implantable device configured to emit an electrical pulse based at least on information related to the detection signal. The implantable devices in the network can wirelessly communicate between each other, either directly or through an intermediate device.